To read our full disclaimer, click here.

It’s finally here…

Welcome to the Healthcare Research Portal!

There has been an immense amount of interest in this new development.

I honestly think this is at least a 3x to the value of a Healthcare Stock Ideas subscription. Not only do you get everything on Substack, but you now have a completely dedicated research portal included in the price.

A huge amount of work has gone into building this, and it genuinely wouldn’t have been possible without your support.

This post serves two purposes.

• First, I’m going to explain how the portal works and why I think it’s so groundbreaking for sharing finance content on Substack.

• Second, it’s the first time I’m sharing the link to the portal itself.

I’ve integrated it seamlessly with Substack, so as long as you have a paid subscription to Healthcare Stock Ideas, you can use that email to log in to the portal.

It’s as simple as that.

The Problem with Substack

Substack has been an amazing platform for sharing ideas and growing the community, but it was never really built for equity research.

As the archive has grown, it’s become harder to find old write-ups, track which companies are in the portfolio, or get a sense of how the body of work hangs together.

The ideas have performed very well so it was a shame people were struggling to find them.

• 65% average peak return since publication. Not the best one. The average.

• 7 of the 19, 37%, up 75% or more at some point.

• Average idea is 226 days old. Seven and a half months.

That’s exactly what this portal solves - a single, clean place to keep the research organised, searchable, and easy to navigate.

So here’s what I’ve built…

The Portal

Start Here

Before you dive into the research, I’d recommend reading through the Foundation pages below. These cover my investment philosophy, the live performance of every idea, and the disclaimers you should know about.

How the Portal Is Organised

On the main page you’ll find two databases that do most of the heavy lifting:

• Recent Updates shows the latest activity across the research library - new write-ups, thesis revisions, anything I’ve added or edited recently. This is the page to check when you come back to the portal.

• Full Research Archive holds every company I’ve covered - 19 of them at launch. The tabs at the top give you curated views - Covered, Watchlist, US Stocks - but the real power is in the filters.

You can slice by sector, geography, conviction level, ticker, and more. For example: filter to US companies, sort by highest conviction, then group by industry. Or pull up everything I’ve ever written on a single sector. This becomes more valuable as the archive grows.

You can also use the site’s main search bar (or the search button at the top of the database) to look up specific tickers or even keywords.

Inside Each Research Entry

Open any company page in the archive and you’ll find:

• Company properties - the same fields you can use to search and filter.

• A Files & Media section linking every Substack post I’ve written on that company, in chronological order.

• A live price chart at the top of every page, so you can see where the stock is trading against the thesis without leaving the portal.

• The thesis itself - a concise breakdown of why the company is interesting, the setup, and what could go wrong. These aren’t carbon copies of the Substack write-ups. They’re tightened, more scannable versions, so you’re getting extra value rather than just rereading the same thing.

• A comments and updates section at the bottom of the page with time-stamped notes for new earnings prints, regulatory filings, and material changes to the thesis.

How to Get Access

It’s pretty easy.

First, make sure you’re a paid subscriber.

To celebrate the launch we are offering 50% off the annual plan for anyone who joins in the next 24 hours:

Claim Your Discount!

Then click the button below and enter the SAME EMAIL you used for your paid subscription.

Access the Portal

This is day one of the portal, so there may be some teething issues. If you run into any, just send me a DM and I’ll get it sorted for you personally.

How to Get a Free Subscription

As promised at the top, we have some paid subscriptions to give away so you can see what the portal is like.

All you have to do is like and restack this post. I’ll pick the winners and give away another couple of subscriptions next Monday, when I share with subscribers how the watchlist is being integrated with the portal.

Share

I hope you like the work we’ve put into this to make consuming finance content easier on Substack.

Thanks as always for your support,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Healthcare Stock Ideas. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

Ten of the nineteen companies I cover had news this week. Two sets of quarterly and full-year numbers, a pivotal trial readout followed the same day by a $50 million raise, a completed Phase 3 enrolment, a refinancing, a debt buyback and a reverse split ahead of a Nasdaq uplisting.

Everything below is what the companies announced, with the figures as reported. My own read on what it means for each thesis lives in the research portal.

Subscribe now

PMV Pharmaceuticals (PMVP)

The busiest week of any name on the list, and the two events are connected.

On 31 August PMV reported updated interim data from the pivotal Phase 2 portion of PYNNACLE, covering 76 platinum-resistant and refractory ovarian cancer patients. Overall response rate was 46%, or 35 of 76 patients, made up of 4 confirmed complete responses, 29 confirmed partial responses and 2 unconfirmed. Median time to response was 1.3 months and median duration of response was 10.0 months. Treatment-related adverse events were mostly Grade 1 to 2, with a 5% discontinuation rate.

The company also said it has FDA feedback supporting an NDA submission for accelerated approval of rezatapopt in TP53 Y220C mutant platinum-resistant and refractory ovarian cancer, targeted for Q1 2027. Primary analysis data from all Phase 2 cohorts is planned for a medical conference in Q4 2026.

Later the same day PMV announced a proposed public offering, then priced it: 22,055,000 shares plus pre-funded warrants over 19,900,000 shares, each with accompanying warrants covering 41,955,000 shares in aggregate, at $1.21 per share and accompanying warrant. The warrants carry a $1.21 exercise price, subject to adjustment following a specified regulatory milestone, and a five-year term. Gross proceeds were approximately $50.8 million before costs, described as oversubscribed, with TD Cowen sole book-running manager and closing expected around 2 September.

Pro-Dex (PDEX)

Fiscal 2026 fourth quarter and full-year results landed on 3 September.

Q4 net sales rose 17% year on year to $20.4 million, with net income of $2.9 million, or $0.87 per diluted share. Gross margin came in at 35%, against 20% in the same quarter last year.

For the full year, net sales rose 16% to $77.5 million and net income was $13.7 million, or $4.12 per diluted share, at a 31% gross margin against 29%. Growth came mainly from the largest customer’s next generation orthopedic handpiece, partly offset by a $6.0 million reduction in repair revenue from that same customer. The February 2026 acquisition of Advanced Precision Machining added $718,000 of revenue across the year.

Hydreight Technologies (NURS.V)

Record Q2 numbers on 31 August. Revenue rose 421% year on year to $28.0 million from $5.4 million, and 12.5% sequentially. Gross profit rose 182% to $5.4 million. Net income was $2.5 million against $0.05 million, and adjusted EBITDA $3.2 million against $0.2 million.

The VSDHOne virtual healthcare and direct-to-consumer platform produced $22.8 million of that quarterly revenue, up from $0.7 million a year earlier. Pharmacy sales reached $26.2 million from $4.5 million.

First-half revenue was $53.0 million, up 434%, with net income of $5.1 million and adjusted EBITDA of about $6.5 million. Cash stood at $20.0 million and working capital at $35.0 million at 30 June, after $8.7 million of operating cash used in the half. Management reaffirmed full-year guidance of approximately $150 million.

Covalon Technologies (COV.V)

Fiscal third quarter results on 27 August. Revenue rose 20% year on year to $10.0 million, gross margin expanded to 67.2% from 46.5%, and net income was $2.8 million against $0.06 million a year earlier, or $0.10 diluted. Adjusted EBITDA more than tripled to $3.0 million from $0.9 million.

Underneath that, Contamination Protection revenue grew 68% year on year and 34% sequentially, and the US Vascular Access channel grew 51%, which the company put at roughly ten times the underlying market growth rate. Cash closed the quarter at $19.4 million with no bank debt, up $2.8 million in three months.

Ion Beam Applications (IBAB)

Half year results on 27 August. Net sales rose 6% to €323.7 million, gross margin improved to 33.7% from 29.5%, and adjusted EBIT rose to €17.6 million from €10.6 million, with the Proton Therapy turnaround contributing €12.3 million of that. The net result swung to €9.3 million from a €2.6 million loss, giving EPS of €0.32. Full-year adjusted EBIT guidance of at least €32 million was reiterated.

Equipment order intake grew 64% to €176 million, with IBA Clinical more than doubling to €148 million on five proton therapy rooms sold. Backlog held stable at €1.6 billion. Net debt rose to €81 million at 30 June from €57 million at 31 March, mainly on working capital movements and temporary ERP-related invoicing delays, with the net financial position expected to improve over 2027.

Then on 2 September IBA joined PFAROS, a European research initiative funded under the Innovative Health Initiative Joint Undertaking bringing together 91 partners to reduce PFAS emissions across the life cycle of medical products. IBA and Bayer co-lead the work on end-of-life and waste management technologies, with IBA assessing its electron beam and Rhodotron technology for PFAS destruction in hospital and pharmaceutical wastewater. No financial terms were disclosed.

Emergent BioSolutions (EBS)

Four releases, two of them commercial.

On 31 August Emergent was awarded a Government of Canada standing offer for NARCAN Nasal Spray 4 mg, running from 1 October 2026 to 30 September 2029 with an option to extend by two further years. It allows federal departments, agencies, Crown corporations, provinces, territories and other designated public sector bodies to purchase the product, and follows an existing five-year standing offer expiring this September. No value was disclosed.

On 1 September came a BARDA contract modification worth approximately $24 million to supply CYFENDUS for anthrax preparedness under federal contract HHSO100201600030C. The release also referenced an earlier 2026 delivery order worth up to $21.5 million for BioThrax. Delivery timing was not disclosed.

On 3 September Emergent completed the repurchase of $75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028, for approximately $68 million in cash, an average of 90.6% of face value. That leaves approximately $364.7 million outstanding. The buyback was funded from cash, with $50 million still available under the asset-based revolving facility, and management said it will watch market conditions for refinancing the rest ahead of the August 2028 maturity.

The fourth was an International Overdose Awareness Day release with no commercial terms.

Verrica Pharmaceuticals (VRCA)

On 27 August Verrica completed enrolment in COVE-2, the first of two pivotal Phase 3 trials of YCANTH in common warts. The study is double-blind, randomised and vehicle-controlled, dosing once every 21 days for up to four applications in patients aged 2 and older.

A pre-specified interim analysis by an independent statistician confirmed no additional patients are needed for adequate statistical power. Topline COVE-2 data is expected in Q1 2027, with the rest of the programme, including COVE-3 which is more than 50% enrolled across US and Japanese sites, anticipated by mid-2027. Common warts affect approximately 22 million US patients and there are no FDA-approved prescription therapies.

CareRx Corporation (CRRX)

A new senior secured credit agreement with National Bank of Canada, announced 27 August. It comprises a $20 million revolving operating facility, a $40 million term loan and a $10 million acquisition and capex facility, giving $70 million available at closing and expandable by up to a further $20 million.

The full term loan was drawn at closing to repay and discharge the existing facility, which the new agreement replaces entirely. Management expects cost savings against the prior facility and framed it as lowering the overall cost of capital while adding dedicated capacity to invest.

Interpace Biosciences (IDXG)

A 1-for-5 reverse stock split took effect on 27 August, cutting shares outstanding from approximately 27.7 million to approximately 5.5 million, with fractional shares rounded up and proportional adjustments to options, RSUs and equity plans.

Stockholders approved it on 20 August. The purpose is to meet the Nasdaq Capital Market minimum bid price requirement ahead of a proposed uplisting from OTCID, where the stock trades temporarily as IDXGD for 20 trading days before reverting to IDXG. Other listing requirements still apply, including a $15 million market value of unrestricted publicly held shares, and the company cautioned there is no guarantee the uplisting completes.

Also this week

Eton Pharmaceuticals (ETON) confirmed it will present at the 2026 Wells Fargo Healthcare Conference, and Hydreight gave notice of its results date ahead of the numbers above.

Quiet this week: Fennec Pharmaceuticals, Innovotech, Journey Medical, NeuPath Health, Precipio, Sanara MedTech, SANUWAVE Health, Vaso Corporation and Viemed Healthcare.

Where the thesis behind each of these lives

A week like this is exactly the problem with following microcaps.

Ten companies moved, some of it genuinely mattering and some of it noise, and the release itself never tells you which is which. A 46% response rate means nothing until you know what the trial had to beat. A $24 million contract modification reads as good news until you check what the thesis was actually waiting for.

Next week I am opening the Healthcare Stock Ideas Research Portal to paid subscribers.

It is the live archive of everything I cover here.

• One page per company, holding the current thesis rather than a pile of old posts: what the business does, why it is an idea, what I think the market is missing, the risks, and what I am watching for next.

• Searchable and filterable by sector, geography and conviction.

• Each page carries a price chart at the top and an auto-updating filings timeline underneath, so every announcement in this roundup is already sitting on the relevant company’s page in date order.

It is not a screener and it is not a list of tips. It is the working file I keep for myself, opened up.

Which also means roundups like this one get more useful from next week.

Every company named above will have a page you can click straight through to, so instead of reading that Covalon’s gross margin went to 67.2% and wondering whether that is the thesis working, you can go and read what the thesis said should happen.

To mark the launch, I am running 25% off the annual plan. It applies to your first year and it is available for a limited time only.

Claim 25% Off the Annual Plan

Paid subscribers get every deep dive, the full archive, and from next week the research portal itself.

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Healthcare Stock Ideas. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

In May I wrote up a debt-free, cash-rich medical-consumables microcap that had just been marked down for a single soft quarter. Revenue was down 15%, and the market read that as the whole story.

My argument was that it was order timing sitting on top of a hospital customer base that had been built faster than the revenue line could show.

The company has now reported the quarter that answers the question.

• Revenue up 20%.

• Gross margin up more than 2,000 basis points.

• Operating expenses flat.

• Adjusted EBITDA more than triple a year ago.

• Earnings per share in one quarter greater than the previous five quarters combined.

• And the cash balance is higher than it was before the company paid out a $4 million special dividend.

The stock has moved roughly 50% since the original write-up, most of it in the days after the print.

For paid subscribers below: the numbers, what changed in the thesis, what didn’t, how the valuation looks after the move, and my updated view from here.

Read more

To read our full disclaimer, click here.

Every so often a position resolves the easy way.

On 29 July, MIMEDX Group agreed to acquire Sanara MedTech.

We initiated coverage on 6 January at $24.00. The deal values Sanara at $35.00 a share.

That is +45.8% in a little under seven months.

The path there was not a straight line.

In March, after an ugly Q4 print, the stock was $18, down 25% from initiation. I wrote an update at that price arguing the business had got cheaper for the wrong reasons and the thesis was intact.

From $18, the deal price is 94.4% higher, in four months.

The Deal

MIMEDX is paying $33.00 in cash plus 0.4735 MIMEDX shares for each Sanara share. On MIMEDX’s five-day average close of $4.22, that works out to $35.00 per share.

Total enterprise value is roughly $350 million, a 46% premium to Sanara’s 30-day volume-weighted average price as of 28 July.

Both boards approved unanimously. MIMEDX is funding the cash portion from existing cash plus a new $300 million term loan from Hayfin Capital Management, with its existing credit agreement repaid and terminated in full.

Closing is expected by the end of 2026, subject to Sanara shareholder approval and regulatory clearance.

One detail is worth pulling out. The March update ran Sanara at 3x forward sales - the low end of the surgical med-tech peer range - and got to roughly $36 a share.

MIMEDX paid $35.

Subscribe now

How It Played Out

The thesis in January was not complicated.

Sanara was a profitable, growing surgical products business. 93% gross margins, 22% revenue growth, trading at about 2.4x EV/Sales while comparable surgical med-tech changed hands at 3-6x.

Management had just done the hard thing, shutting down the loss-making Tissue Health Plus segment to become a clean surgical pure-play. The distributor model was scaling revenue on flat internal headcount: 22% growth on the same 40 field reps they had run for three years.

Sitting on top of that was OsStic, a synthetic injectable bone adhesive with FDA Breakthrough Device Designation, which the market valued at zero.

Then Q4 landed and the stock fell apart.

Revenue grew 5%. Operating income missed by 66%. A noncash impairment hit the P&L. And the debt balance, which the original thesis expected to come down, went up instead - from $30.7 million to $46 million, with interest expense more than doubling to $6.8 million.

The stock went to $18.

The March update argued the headline was hiding the progress.

The 5% growth was a hurricane comp, with Q4 2024 carrying roughly $1.8 million of one-off BIASURGE demand from a saline shortage. Strip it out and Q4 grew 13%. Strip the impairment and operating income grew 28%. The THP wind-down was complete and under budget. A Vizient contract had just opened roughly 1,800 new facilities for the fastest-growing product, close to doubling the addressable base overnight.

The one thing that update would not wave away was the debt. No credit until the April refinancing actually happened.

It never happened. A buyer refinanced the whole company instead.

What the Trade Teaches

The price fell 25%. The business didn’t.

Between the January thesis and the March update the stock lost a quarter of its value. Over the same stretch the business reported full-year revenue crossing $100 million for the first time, up 19%. Gross margin up 200 basis points to 93%. Adjusted EBITDA up 86% to $17 million. Operating cash flow moving from essentially nothing to $6.8 million, or roughly $16 million stripping out the THP wind-down. The distributor network went from 350 partners to over 450, facility customers to over 1,450, and the loss-making segment was shut.

Every operating line moved forward. The share price was the only thing that went backwards.

The work in that window was not deciding whether the stock looked cheap.

It was checking, line by line, whether anything in the thesis had actually broken. In my opinion nothing had.

Optical mess stops mattering the moment a buyer turns up.

What broke the stock in March was a hurricane-inflated prior-year comparison, a noncash impairment charge and a GAAP loss line. All three are screen-level artefacts. None of them changed how much collagen product Sanara sold, what it cost to make, or how many hospitals were buying it.

Four months later MIMEDX paid a 46% premium.

An acquirer normalises the comp, adds back the impairment and refinances the debt onto its own balance sheet, because it is buying the asset rather than the quarterly presentation of it.

Accounting ugliness is a discount available to whoever is willing to look underneath it.

This could have gone the other way, and the debt is the reason.

Debt went from $30.7 million to $46 million during 2025 and interest expense more than doubled to $6.8 million at a 13.5% rate.

The April 2026 refinancing the original thesis assumed would happen never did.

The March update flagged this as the open risk and declined to give credit for a refinancing until it landed.

We never found out how that resolved, because a buyer took the entire balance sheet out.

That is a good outcome arriving from outside the thesis.

Had no buyer turned up and growth come in at the low end of the 13-17% guide, the same balance sheet would have been exactly the problem the March note said it might be.

Leverage is what separates a thesis that is merely slow from one that does permanent damage, and the honest reading here is that the risk was correctly identified and then resolved by luck rather than by anything in the analysis.

Subscribe now

Where That Leaves Holders

The stock trades close to, but a shade below, the deal value. That is the usual arbitrage discount for time and completion risk.

A modest spread remains for holders willing to sit through closing and carry the regulatory and shareholder-vote risk. That is a merger-arb decision rather than the idea we underwrote in January, and it is a different game with different skills.

For our purposes the thesis has done its job. The gap we identified has closed. There is no mispricing here left to be right about.

The Bottom Line

Sanara did what we hoped, faster than expected and by a route we did not model.

A profitable, growing, 93%-gross-margin surgical business at half its peer multiple, bought in January, held through a quarter that read far worse than it was, and taken out at $35 in July.

The part I would repeat is watching the operating lines rather than the quote when the stock fell. The part I would not claim credit for is the debt, which was the one thing flagged as most likely to go wrong and which got solved by an acquirer rather than by management.

+45.8% from initiation in January. +94.4% from the March update. Coverage closed.

There will be no further updates on Sanara MedTech.

As always, this is not investment advice. Do your own research, consider your own risk tolerance, and make your own decisions.

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Healthcare Stock Ideas. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

In November, we published a thesis on a profitable healthcare company trading at 71% of cash per share.

Trading at 71% of Cash Per Share, Quality Compounder, Record Backlog Going Into Q4

In February, with the stock up 30%, we revisited after two key catalysts - a divestiture and a GE HealthCare contract extension - landed in rapid succession.

Trading at 91% of Cash Per Share, Up 30%, and the Biggest Risk Just Disappeared

In May, with Q1 in hand and the stock up 64%, I wrote that the thesis had played out as expected but the easy part was over.

Vaso Corporation (OTCQX: VASO) | Up 64% From Entry, First Operational Data Lands

The stock is now $0.26, up roughly 85% from our entry point.

It moved 38% yesterday alone.

On Monday, VASO announced it had completed the sale of NetWolves Network Services to COEO Solutions for $14.5 million in cash.

The market read that as a windfall. I read it as the end of the thesis I originally wrote.

This post is my reasoning why…

Read more

To read our full disclaimer, click here.

Most investors have one label for this company, and it is two years out of date.

Failed launch.

The product got approved and then went nowhere. The stock lost more than 85% of its value in a year. A reverse split followed, then an emergency financing to clear the debt.

People filed it under broken biotech and moved on.

That label is the opportunity in my opinion.

Because what this is now is a turnaround, and it is already working. Management rebuilt the way the product reaches the customer, and the demand curve turned before anyone bothered to update the story. Volumes grew 51% year-over-year last quarter and set an all-time record in March. April beat March. Gross margins are 87%. The debt is gone.

Subscribe now

Here is what makes that interesting.

A turnaround that has already turned is a very different proposition to one you are still betting on. The evidence is in the numbers rather than in the pitch, and the market has not repriced it.

Then there is the second layer, and it is the part I like most.

Sitting on top of the commercial business are two late-stage programmes the market is currently valuing at zero. One goes after a market more than three times the size of the one the company sells into today, in a condition with no approved treatment anywhere in the world, and a partner is funding roughly 90% of the trial bill. The other already has an agreed path with the regulator.

Free optionality, on somebody else’s balance sheet.

So the category here is simple:

A microcap turnaround at the inflection point, with a partner-funded pipeline attached at no cost, in a stock still priced on the old story.

Here’s everything you need to know…

Read more

To read our full disclaimer, click here.

For three years, one number kept this stock in a cage.

The province that funds most of its business kept threatening to cut the rate it pays per bed. So investors treated the whole company as a coin flip on a government decision, and the multiple stayed on the floor.

This spring, the cut was cancelled.

Not deferred. Cancelled, and the rate maintained going forward.

The biggest overhang on the stock was just removed - replaced by a much smaller, capped headwind - and I don't think the market has repriced it.

Here is what makes that interesting.

The overhang lifted at the exact moment the business hit its inflection. Last quarter, revenue, EBITDA, margin, and net income all moved up together, with profit growing faster than revenue. That is operating leverage finally showing through, and margins are now closing in on double digits.

Underneath it: a profitable, dividend-paying business that already holds about 18% of its market, with plenty of room to keep taking share, a demographic wave at its back, and a balance sheet cleaner than it has been in years.

Subscribe now

I think the setup is asymmetric.

My base case points to a double from here, the bull case to more than 3x, and even my bear case limits the downside to roughly -25%.

Those are illustrative scenarios I use to frame the range, not forecasts, promises, or investment advice. The full assumptions behind each one are laid out below, and you should do your own work before drawing any conclusions.

Read more

Every deep dive you read here starts somewhere. Before the thesis, before the valuation work, before the risk section - there’s a list.

This is that list.

Each month going forward I’m now sharing my watchlist, the names I’m actively researching, where they sit in the pipeline, and what would move them up or knock them off.

Some of these will graduate to full deep dives. Some will fall away as I do the work. That’s the point - you’re seeing the funnel, not the finished product.

This month there are five names: a post-bankruptcy turnaround the market left for dead, a $5 million nano-cap with a founder who owns half of it, a botched pharma launch getting fixed by serious money, a quiet Canadian compounder about to show its operating leverage, and a medtech that just won a first-of-its-kind FDA approval.

Here’s what I’m watching, and why.

Read more

To read our full disclaimer, click here.

The Clinical Edge has a new name. It’s now Healthcare Stock Ideas.

Same person writing it, same research, same process - so if this email looks like it’s from someone new, it isn’t. It’s still me.

Here’s the honest reason for the change.

With the old name, I never got the reach or the discoverability this page should have had. “The Clinical Edge” just didn’t tell anyone what they were actually getting.

“Healthcare Stock Ideas” does. There’s no mistaking what this page is about now 😂.

And I think it deserves the reach…

Subscribe now

Let me start with where the page is at:

• 17 ideas published.

• 50% average peak return since publication.

• 6 of the 17 - 35% - up 75% or more at some point.

• The average idea is 169 days old. About five and a half months. The newest is nine.

But I lead with peak return for a reason.

This page is built for asymmetric setups, where the mispricing sits in the optionality and the biggest move usually comes early, before the crowd catches on.

Peak return is the honest headline for what this approach is designed to produce. And this is what micro-cap healthcare can do when the research is right.

That track record is why the rest of this matters.

Now the part I told you to stick around for…

I’ll be honest with you: this page has been priced well below the substacks in this niche performing at the level we are. That changes Monday.

From Monday, it’s $699 a year or $85 a month.

Until then it stays exactly where it is now - $400 a year or $50 a month.

After Monday, it will never be cheaper than it is today.

If you’ve been sitting on the fence, this is the moment. Subscribe or upgrade before Monday and you lock in the current price for as long as you stay subscribed, even after it rises.

Lock in Today's Price

The goal is simple going forward, and I’m writing it down here so you can hold me to it:

I want to become the number one healthcare newsletter on Substack.

To everyone already supporting the page - thank you. It’s your support that makes all of this possible.

Have a great weekend,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Healthcare Stock Ideas. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

In 1993, Peter Lynch wrote a column called “A Chicken’s Guide to Biotech.”

It was written for people who liked the idea of biotech but couldn’t stomach the risk.

The premise was simple: here’s how to get exposure to the sector without betting on some tiny lab that might blow up overnight.

A chicken’s way out.

I’ve read that column more times than I can count.

And here’s the funny thing.

Buried inside Lynch’s “play it safe” advice is the exact framework I use to think about healthcare microcaps today.

He just told his readers not to use it.

Let me show you what I mean…

Subscribe now

The Setup Hasn’t Changed in 30 Years

Lynch was writing in the middle of a biotech sell-off.

Investors had lost faith. They’d lost money.

And the roughly 225 publicly traded biotech companies of the era suddenly couldn’t raise a dime.

In his words, they could no longer “depend on the public generosity to keep them solvent.”

The new-issue market had shut down. The eager crowd of buyers had vanished.

So the cash-poor labs were forced into mergers, joint ventures, and licensing deals with richer partners - mostly the pharmaceutical giants.

It’s worth reading that twice, because it describes the biotech market almost perfectly right now.

A brutal drawdown. A frozen financing window. Dozens of small companies trading for less than the cash sitting in their bank accounts, forced to do deals just to survive.

To most investors, that’s a horror story.

I tend to see it differently.

Distress is what creates the mispricing. When good science is forced to sell itself cheaply, that’s often when the most interesting opportunities appear.

Lynch’s Chicken’s Way Out

Lynch’s first piece of advice was to buy the pharmaceutical giants.

The logic was sound. The giants had a problem - their blockbuster patents (Cardizem, Procardia, Ceclor) were expiring, and generics were eating into their margins.

But the biotech sell-off handed them a gift: the chance to buy cutting-edge science, with fresh patents, on the cheap.

So Lynch pointed readers toward names like Schering-Plough, which was spending $125 million a year on biotech R&D and had a licensing deal with Biogen for alpha interferon. It traded at about 15 times earnings, growing 15% a year.

Safe. Sensible. Diversified.

And it’s a perfectly reasonable way to invest.

It’s just not where the most dramatic outcomes tend to come from.

A large pharma giant that adds a promising biotech partnership doesn’t usually re-rate by a factor of ten.

The small company on the other side of that deal is a different matter.

Subscribe now

The Part Almost Everyone Skips

Lynch then offered what he called the “reverse chicken’s approach.”

Look at the biotech companies being absorbed by the giants, or the ones doing the major joint ventures.

His reasoning is the most important idea in the whole column:

When Roche spent $2.1 billion to acquire 60% of Genentech, Lynch said it was “a pretty good sign there’s some value left in the remaining 40%.”

That’s the heart of it.

A deep-pocketed pharma giant, with armies of PhDs doing due diligence, validating the science by writing an enormous check - and the public market still pricing the rest at a discount.

Lynch said it was the Roche-Genentech deal in September 1990 that finally convinced him the biotech industry was for real.

It took four months for Genentech to begin climbing, from $21 to $39.

This is close to how I think about The Clinical Edge.

Let the giants and the specialists validate the science. Then look for the small, overlooked company where the market’s story still hasn’t caught up to the scientific reality.

Narrative dislocation. The market lags the science. That gap is the whole point.

The Real Blueprint: Amgen

The best part of Lynch’s column is the Amgen story, and it’s a masterclass in optionality.

Fidelity’s biotech analyst, Mike Gordon, spotted Amgen around 1989 and was begging the in-house managers to load up while it traded at $5 to $7.

When Amgen’s first real product, Epogen, got final FDA clearance, the stock hit $10.

By the end of 1991, it was $76.

Ten times your money in about two years.

But here’s the lesson Lynch wanted you to take away, and it’s one most investors get completely wrong:

“Just because the good news is already out doesn’t mean it’s too late to invest.”

Amgen roughly doubled again in 1991-92 - after it had already won its patent battles, after the FDA approval, after the “obvious” news was public.

The optionality didn’t disappear when the first catalyst hit. It carried on.

It’s a useful reminder that the instinct to sell the moment a thesis starts working is often the wrong one.

The Volatility Is Real

Lynch was honest about the pain, and it’s only fair to be the same.

Not long after Amgen reached $70, the entire biotech sector dropped - because one unrelated company failed an important clinical trial.

Amgen was dragged down in sympathy. $70 to $35. A $10 billion company cut to $5 billion, on news that had nothing to do with it.

In Lynch’s words:

“An investor in biotech shares has to have a strong stomach, and it helps to be farsighted as well.”

But what he says next is the part worth underlining, because it’s essentially a screen:

When the whole sector gets hit, look for bargains - “companies with share values close to their cash holdings.”

With one crucial filter to keep the risk contained.

Limit the search to companies that already have drugs on the market, or at least in clinical trials, with real revenue coming in.

Cash on the balance sheet. Real products. Actual revenue. Bought during a sector-wide panic.

Regular readers will recognise that, because it’s almost word for word how I screen for healthcare microcaps trading near or below their own cash.

Here is one here:

Lynch wrote the filter in 1993. It still works.

Subscribe now

Where I Personally Go the Other Way

The way Lynch closes the column is, more or less, the way the masses have always been advised on biotech.

It’s too volatile. Too complex. Leave it to the professionals. Buy a diversified fund and don’t try to pick the small names.

There’s nothing wrong with that advice. But it is what almost everyone is told - and when the whole crowd is funnelled toward the same safe options, the giants and the funds and the index, the small overlooked companies get left for dead.

That neglect is the opportunity.

So my strategy deliberately goes the other way. Into the undiscovered, unloved corner of healthcare the masses are steered away from.

But going against the crowd without protection is just recklessness with extra steps.

So I take the very things Lynch said to look for in biotech and turn them into my margin of safety:

• Cash on the balance sheet, a product on the market or in trials, and real revenue coming in - the exact filter Lynch laid out, so the downside is anchored to something tangible.

• Multiple shots on goal - pipeline diversity, platform technology, more than one way for the thesis to work.

• Real problems - genuine unmet medical need, a clear regulatory path, customers willing to pay.

• Founder-led teams with their own money on the line.

Then comes the part that ties it all together: how I actually build a position.

I start small. The initial position is deliberately modest - sized so that if the thesis is simply wrong, it does no real damage to the portfolio.

I only add as catalysts approach and the data backs up the story.

And once a position is working, I’m in no rush to trim it.

That combination - operating where the crowd won’t, but insisting on cash, revenue, optionality and alignment before I do, then starting small and adding into strength - is the margin of safety.

It’s what lets me take controlled positions in an area everyone else is told to avoid.

The Takeaway

Peter Lynch wrote a guide for people who were nervous about biotech.

But, for me, a far more interesting approach was sitting in the same column the whole time.

Buy good science during a panic. Insist on cash on the balance sheet, real products, and real revenue. Let the giants validate the breakthroughs. Hold through the volatility. And think hard before cutting a position the moment it starts to work.

Lynch’s column was the careful, conventional route - the one the masses are pointed toward.

My strategy takes the opposite path on purpose: into the small, overlooked names the crowd is told to avoid, with cash, revenue, optionality and alignment as the margin of safety, and small, controlled position sizes as the seatbelt.

That corner of the market - small and overlooked healthcare companies - is exactly where this newsletter goes looking each week.

The Clinical Edge exists to do that work: 2-4 healthcare microcaps a month with asymmetric risk-reward, multiple shots on goal, aligned management, and mispriced optionality.

Paid membership is available here:

Subscribe now

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

The company I’m sharing today first appeared last week over on Multibagger Ideas - but it deserves a second look here, because I think it’s genuinely one of the more interesting setups I’ve come across in a while.

It’s a rare one. The kind where several boxes get ticked at once - boxes I almost never find stacked together:

• A genuine world leader - an estimated 60-71% of the global proton therapy market - in a structurally growing corner of cancer care

• Toll-bridge economics: every machine sold turns into a multi-decade service annuity, now more than half of a €1.6 billion backlog

• Double-digit revenue growth - €620 million in 2025, up 24% - with profitability guided to roughly double by 2028

• That same €1.6 billion backlog set against barely €500 million of market cap - over 3x the whole company, already under contract

• Founder-rooted and insider-aligned, through the holding structure that controls the ~20% reference shareholder

• A self-funding balance sheet - just €57 million of net debt and a live buyback

• And the one that makes it rare: a 31.3% stake in the world’s largest emerging supply of actinium-225 - cancer’s next-wave isotope - sitting in none of the guidance, with a second free option in astatine-211 behind it

The company is…

Read more

To read our full disclaimer, click here.

The track record so far:

• 16 ideas published.

• 47% average peak return since publication. Not the best one. The average.

• 6 of the 16 - 38% - up 75% or more at some point.

• Average idea is 155 days old. Five months. The newest is 26.

Below is a short thesis summary of my favourite 10 ideas in random order.

A few are free for everyone to read; most sit behind the paywall, where you also get every new idea as it’s published and ongoing coverage of all of them.

As a thank you, I’m giving away just two 25% discount codes on the annual plan - the first two subscribers to redeem them get the rate:

Claim now!

Stock 1

A telehealth infrastructure company building the regulatory and operational backbone that every distributed-healthcare business in America needs, in a market projected to grow from $6.3 billion in 2024 to $10.7 billion by 2033. The platform spans three verticals: a network of 3,000+ independent registered nurses operating under the company’s medical license, a franchise solution helping med spas and IV clinics navigate telehealth regulation, and its real growth engine - a direct-to-consumer platform that lets entrepreneurs launch a 50-state-compliant telehealth company for $5,000/month, with everything from GLP-1s to peptides, TRT, and hair loss running through it. Over 12,000 licenses have sold since launch, now live across all 50 states. Q1 2026 revenue hit a record C$24.9 million, up 449% year-over-year, while operating expenses collapsed from 36% to 9% of revenue and adjusted EBITDA margin expanded to 13.1% - the third consecutive quarter of margin expansion. Management reaffirmed full-year guidance of at least C$150 million in revenue. As regulation tightens across digital health, the compliance-heavy platform becomes more valuable, not less - the moat working exactly as designed.

Stock 2

A profitable, multi-segment healthcare company the market spent years valuing at less than the cash sitting on its balance sheet. The business is anchored by an exclusive professional sales and services relationship with a major imaging OEM - selling and servicing diagnostic equipment across the US - now contractually secured through 2030, removing the single biggest risk to the thesis. Roughly 87% of its IT-segment revenue is recurring, providing a defensive base, while deferred revenue (cash already collected for services not yet delivered) recently hit a record - future earnings effectively banked. After divesting its weakest subsidiary, core revenue is growing, gross profit is expanding, and losses are narrowing as the leaner cost structure flows through the P&L. The story has matured from a pure below-cash arbitrage into an operating turnaround: a debt-free, cash-rich microcap whose record backlog gives it a clear runway to convert demand into earnings, quarter by quarter.

Stock 3

A profitable medical device manufacturer that makes the precision-engineered powered surgical instruments - handpieces, drivers, and shavers with tolerances measured in microns - used to install orthopedic implants, rather than the implants themselves. For over a decade it has been the critical supplier to one of the world’s largest medical device companies, which accounts for roughly three-quarters of revenue. The market treats that concentration as a fatal flaw; the reality is that switching costs on an FDA-approved product line are enormous, customer relationships run for decades, and the supply agreement has now been extended for years, securing the core franchise. After co-developing a next-generation handpiece platform with that customer, the company has moved into full production, with a multi-month backlog providing real revenue visibility. The model throws off significant operating leverage - incremental volume runs through an existing ISO 13485-certified facility with minimal added investment - and recent results show it, with double-digit revenue growth, expanding operating income, and net income that quadrupled. A bolt-on machining acquisition added capacity, and a legacy equity stake in a surgical-robotics company - acquired by a major orthopedics player - delivered realized cash gains plus a long-term supply agreement that could make this the critical supplier to a top-tier robotic-orthopedics platform. It trades at a low-teens forward earnings multiple and a fraction of the sales multiple typical for medical device peers.

Stock 4

A single-product specialty pharma company whose drug is the only on-label therapy in the U.S. for protecting against the permanent hearing loss caused by cisplatin, one of the most widely used chemotherapy agents in oncology. The drug carries roughly 96% gross margins, so nearly every incremental sales dollar drops through a largely fixed cost base into operating leverage. The original pediatric indication built the company to its first ~$44.6 million in annual sales, but the real engine is the adolescent and young adult (AYA) and adult population - roughly ten times the size of pediatric - which is now outgrowing the pediatric base as adoption expands across testicular, cervical, and head-and-neck cancers. The field organization has scaled its prescriber target from ~1,300 to over 5,000, and the patient-support program is converting a high share of referrals into completed infusions. The company is now GAAP-profitable with positive operating cash flow, carries zero debt and a healthy cash position, and has delivered six consecutive quarters of sequential revenue growth. A patent settlement secures U.S. market exclusivity to at least September 2033, and an optionality stack sits on top of the core story: European launches through a partner, ongoing Japanese registration discussions, and a widening clinical evidence base in adult tumor types - none of which is yet in the revenue line.

Stock 5

A rare disease pharmaceutical company that acquires rights to orphan drugs - therapies for patient populations so small that Big Pharma can’t be bothered - and then does what the previous owners never did: actually invests in commercializing them. The model carries unusually attractive economics: 70–75% gross margins, high switching costs (once a pediatric patient is stable on a therapy, physicians don’t switch), strong reimbursement with few alternatives, limited competition, orphan-drug regulatory exclusivity, recession resistance, and operating leverage as a flat sales infrastructure scales across more products. The portfolio has grown to 10 commercial products plus a deep pipeline of late-stage assets, funded through disciplined, cash-financed acquisitions with no dilution. The company has now turned GAAP-profitable with EBITDA margins inflecting higher, on the back of a long streak of consecutive quarters of sequential revenue growth. Its newest approved drug landed an unexpectedly broad label - no age restriction - expanding the addressable population from a few thousand children to roughly 9,000–10,000 adults at ~$80,000 per patient per year, with patent protection running to 2044. A separate bolt-on product, the only FDA-approved treatment for a time-sensitive infant condition, was just relaunched through a streamlined specialty-pharmacy channel. Management is targeting the largest rare disease portfolio in the U.S. (13–14 products), a $200 million revenue run-rate exiting 2027, 50% adjusted EBITDA margins by 2028, and $500 million in revenue by 2030 - and has so far done what it said it would do.

Subscribe now

Stock 6

The operator of Canada’s largest network of dedicated chronic pain clinics - regulated medical facilities staffed by specialists, funded almost entirely (97–99%) by provincial government health insurance. This is a private provider of public health services, delivering hospital-grade pain treatment (nerve blocks, radiofrequency ablation, ketamine and lidocaine infusions, and newer high-margin procedures) in community clinic settings that give patients faster access while costing the system less. The demand is structural, not cyclical: one in five adults lives with chronic pain, specialist wait times can stretch 18 months, and clinic waitlists run into the thousands - a public system that simply cannot keep up with an aging population. Recent results show clear operating leverage, with revenue growing in the mid-20s percent while adjusted EBITDA nearly doubled as capacity utilization climbed past 80% across a right-sized clinic footprint. The company has now posted positive EBITDA for 27 consecutive quarters, carries minimal net debt with one of the cleanest cap structures on its exchange (no warrants, no convertibles), and trades at roughly half the EV/EBITDA multiple of comparable Canadian healthcare clinic operators. With acquisition financing secured and 10–12 targets under evaluation in a fragmented market, the CEO buying shares personally, and a buyback running, there are multiple independent paths to value: organic growth, geographic expansion into new provinces, higher-margin service mix, and accretive M&A.

Stock 7

A profitable, debt-free advanced medical-consumables company selling into hospitals across three areas - vascular access, advanced wound care, and surgical consumables - all built around reducing healthcare-associated infections. Its anchor products cover and protect IV line connections, addressing an enormous clinical problem: roughly 90% of hospital patients get an IV line, more than a billion are placed each year, and every one is a potential pathway for bloodstream infection that costs far more to treat than to prevent. The business runs at 58% gross margins - 500 to 1,000+ basis points above much larger med-tech peers - is completely debt-free with net cash worth roughly a third of its market cap, and is owned about 50% by insiders, with the board alone holding around half the shares. The model is land-and-expand: win an account through clinical evaluation, then spread product across units and buildings, an annuity-like consumables base reflected in 99% retention of its top-50 hospital accounts. The structural change is a shift from selling hospital-by-hospital to securing system-wide approvals at Integrated Delivery Networks - large health systems with hundreds of sites under one purchasing umbrella - including marquee wins at nationally known medical centers. Each network approval clears the institutional barrier once and then feeds years of facility-by-facility pull-through. Because new accounts start small and convert slowly, the customer base has been built ahead of the revenue, and the stock trades near 1x revenue while debt-free med-tech consumables peers with lower margins trade at multiples of that.

Stock 8

A multi-engine home-healthcare platform that keeps very sick patients out of the hospital by delivering the equipment and clinicians they need directly into their homes, paid a recurring monthly fee - mostly by Medicare - for as long as each patient stays on therapy, which for the sickest can run years. The core business places in-home ventilators for end-stage COPD patients, supported by respiratory therapists and proprietary adherence software, generating durable recurring revenue. Layered on top are three growth engines: a fast-growing sleep apnea franchise with printer-and-ink economics (rent the machine, resupply masks and tubing), tailwinded by GLP-1 adoption pushing more patients in front of doctors; a newly acquired maternal-health line (breast pumps) that plugs into the company’s nationwide insurance contracts to reach markets the target could never serve alone; and a supporting base of oxygen, airway-clearance, and clinical staffing that feeds hospital referrals. The real moat is the operational scaffolding underneath all of it - payer contracts in every state, billing and compliance systems that actually get paid, clinical technology - built over nearly two decades and hard to replicate, so each new product line rides on top without rebuilding it. Recent results showed ~20% revenue growth, record adjusted EBITDA, and free cash flow that more than doubled as the mix shifted toward less capital-intensive categories, all on a near-net-cash balance sheet with an active, renewed buyback. The biggest overhang of the prior two years - a tighter Medicare coverage standard for in-home ventilation - has shifted from active threat to improving setup, with the more objective new criteria arguably favoring scaled providers. It trades around 5x forward EBITDA while home-care and DME peers have historically fetched 8–10x.

Stock 9

A molecular diagnostics company that the market left for dead behind a misleading headline - reported revenue fell sharply after it lost Medicare reimbursement on one legacy test - while the core business underneath was quietly thriving. Having exited that test, it’s now a pure-play thyroid diagnostics company, with 100% of revenue from two proprietary thyroid cancer tests that help physicians avoid unnecessary surgery. The core franchise has been compounding at double-digit rates, driven by rising test volumes, more accounts, and higher revenue per test, while the shift to a thyroid-only model has expanded gross margins toward the mid-60s and pushed adjusted EBITDA margins higher. This is a profitable, cash-generating, debt-free business - it paid off 100% of its debt - not a cash-burning turnaround. The capital structure has been cleaned up: the two private-equity sponsors that control roughly 84% of the company voluntarily converted their preferred stock to common, giving up their liquidation preference - a clear signal they see the upside in the equity, not the safety of the preferred. Management has stated its intent to uplist to Nasdaq, which would open the door to institutional investors barred from the over-the-counter market, improve liquidity, and potentially bring analyst coverage. It trades at a low multiple of forward revenue while the thyroid diagnostics market leader trades many times higher, despite this company growing faster with strong margins. The risks are real - reimbursement exposure, concentrated ownership, and thin liquidity - but the business is executing on every leg of the thesis.

Stock 10

A nano-cap cancer diagnostics company that just quietly hit an inflection the market hasn’t priced in. It runs a CLIA-certified molecular and cytogenetic laboratory delivering academic-level diagnostic accuracy - every report reviewed by faculty-trained pathologists - to community oncologists who lack in-house testing, catching the diagnostic errors that generic reference labs miss. The model has two inherently recurring streams: pathology services (~90% of revenue), where onboarded oncology practices send biopsy and blood samples month after month with high switching costs from credentialing and insurance enrollment, and a faster-growing products division (~10%) selling proprietary reagent kits and assay panels that labs reorder as supplies deplete - at structurally higher (~60%) margins. After working through a billing disruption caused by a cyberattack on its clearinghouse vendor, the company turned positive on both EBITDA and operating cash flow for the first time in its history, while growing revenue ~30% year-over-year. Operating leverage is the story: revenue is climbing while operating expenses stay roughly flat, so each incremental test or kit falls heavily to margin - gross margins have risen toward the high-40s with management targeting 50%+, and the mix shift toward the higher-margin products division could reshape the margin profile as it scales to 20–25% of revenue. It trades at a fraction of the EV/Sales multiple of diagnostics peers, leaving room to re-rate on continued execution alone.

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

It’s been a while since the last update on this company.

And it’s been a very choppy year.

Back in August, the original thesis was published at C$2.90. The stock ran past C$5 as the business executed quarter after quarter. Then the Q3 earnings call happened - management couldn’t clearly explain their own numbers, KPIs shifted mid-call, and the stock dropped 26% in a single session.

The slide continued into the new year, with the stock touching a low of C$2.39 at one point.

Then Q1 2026 earnings landed earlier this week.

The stock ran quickly up to C$5.34, before settling back down to C$4.86.

That brings our total return since the original thesis to roughly 68%.

But here’s what makes this situation interesting:

• The business never broke.

• Revenue this quarter grew 449% year-over-year.

• Third consecutive quarter of margin expansion.

• Operating expenses fell from 36% of revenue to 9%.

• Cash position strengthened.

• Full-year revenue guide of at least C$150M reaffirmed.

What’s interesting is what management is not doing - namely, taking analyst questions on earnings calls. Two quarters in a row now, no Q&A.

The numbers are loud enough that they can probably get away with the silence. For now.

The asymmetry from the original C$2.90 entry has compressed. But on the 2026 guide, the stock is still trading at a meaningful discount to telehealth peers.

Today’s company is...

Read more

To read our full disclaimer, click here.

In November, we published a thesis on a profitable healthcare company trading at 71% of cash per share.

In February, with the stock up 30%, we revisited after two key catalysts - a divestiture and a GE HealthCare contract extension - landed in rapid succession.

The stock is now up roughly 64% from our entry point.

Q1 2026 earnings, released May 15th, are the first operational data point under the evolving leadership structure. The thesis has played out as expected. But the easy part in my opinion is over.

Here’s what the numbers said, what they mean, and where the thesis stands today.

Subscribe now

Where We Started, Where We Are

A quick reset before the numbers, because context matters here:

• November 2025: $0.14 stock price, $24M market cap, $35M cash → trading at 71% of cash

• February 2026: $0.18 stock price, $31.67M market cap → trading at 91% of cash

• May 2026 (today): $0.23 stock price, $40M market cap, $38.5M cash → trading at ~104% of cash

The structural mispricing we identified is essentially closed. The stock now trades at roughly its cash value, which means the easy arbitrage - buying a profitable, operating business for less than the bank account - is gone.

What’s left is the operating business itself.

So Q1 matters more than any quarter we’ve covered so far.

It’s the first chance to see whether the operational thesis - that management can turn a record backlog into actual earnings - is real.

What Q1 Actually Showed

The headline number looks soft: revenue of $19.4 million, down 0.5% year-over-year.

That’s misleading. Once you back out the healthcare IT reseller VASO divested in November, the same comparison shows revenue up 4.8%, and gross profit up 5.8%.

That’s the cleaner read.

Three things stood out underneath the headline:

1. The GE segment is delivering exactly as the contract extension implied. Professional sales services revenue was up 6.1% year-over-year, driven by higher imaging product deliveries from GE HealthCare and a higher blended commission rate. This is the segment that was contractually secured through 2030 in December. The first full quarter under the extended agreement confirms the relationship is producing - not just preserved.

2. Deferred revenue grew to a record $39.5 million, up 11.6% year-over-year. This is the metric that matters most for the long-term thesis. Deferred revenue is cash collected for services not yet delivered - it represents future earnings already in the bank. An 11.6% increase against a roughly flat revenue line means the booking machine is accelerating faster than the conversion machine. That’s both the opportunity and the bottleneck we flagged in the original post.

3. Net loss narrowed to $887 thousand from $1.1 million. Modest, but moving in the right direction. Adjusted EBITDA also improved slightly, from negative $1.12M to negative $1.07M. The post-divestiture business is leaner, and the early signs suggest the trim is showing up in the P&L. Q1 is seasonally the weakest quarter for VASO - management explicitly reminded investors that they’ve historically been more profitable in the later quarters of the year.

The Cash Burn Looks Worse Than It Is

The line item that will spook a casual reader: $12.6 million in cash used in operating activities, against $566 thousand in the year-ago quarter.

Management’s explanation: timing.

Payments expected in March arrived in April, distorting the quarter-end snapshot. That’s consistent with the deferred revenue growth, and the May 8 cash balance of $38.5M tells you the cash position remains healthy.

Cash per share is still roughly $0.22 against a $0.23 stock price.

I take the timing explanation at face value for now, but it’s the kind of thing that becomes a problem if it repeats. Q2 will be the tell. If operating cash flow returns to near breakeven or better, this was noise.

If it doesn’t, the working capital story needs a harder look.

Subscribe now

The Real Concern: SG&A

The one number I’m watching closely is SG&A. It rose 2.6% to $12.7 million, despite the divestiture of an entire subsidiary that should have meaningfully reduced overhead.

Management’s breakdown: higher personnel and travel costs, plus higher consulting and accounting expenses, partially offset by savings from the IT divestiture.

Two ways to read that.

• The optimistic read is that VASO is investing ahead of expected growth - David Mueller building out infrastructure, the team gearing up to convert the growing deferred revenue base.

• The pessimistic read is that cost discipline is loose, and the divestiture savings are being absorbed by overhead growth before they ever reach the bottom line.

You don’t get a verdict on this from one quarter.

But it’s the number I’ll be triangulating against revenue and gross profit growth for the rest of 2026.

Updated Risk Profile

Where the original risks stand after Q1:

• GE Partnership Deterioration - Still eliminated through 2030. Q1 confirms the relationship is producing, with the segment growing 6.1%.

• Operational Improvements Don’t Materialize - Early but encouraging. Deferred revenue up 11.6%. Core revenue up 4.8% ex-divestiture. Net loss narrowing. The conversion of bookings to revenue is still the central question, and the answer won’t be clear until at least Q3.

• Macro Headwinds - Slightly elevated. Management explicitly cited “growing uncertainties in the general business environment” and called out US tariff policy as a risk factor in the forward-looking statements. The 87% recurring revenue base in the IT segment remains the defensive anchor.

• Continued Illiquidity - Still a $40M market cap on OTCQX. Anyone sizing a position needs to size it for the door.

• New risk: The valuation cushion is gone. When we first wrote about VASO, you were paying 71 cents for a dollar of cash, plus the operating business for free. At $0.23, you’re paying for both. That changes the risk-reward materially. The thesis no longer has the “cash is a floor” safety net it had in November.

Where I Stand

Six months ago, VASO was a profitable company trading below cash with two specific catalysts and a partnership question mark.

Today, the partnership is secured through 2030. The weakest subsidiary is gone. Core revenue is growing. Deferred revenue is at a record. The net loss is narrowing. Management has done what it said it would do, and the stock has responded.

What’s left is a different kind of bet. The structural mispricing is closed. From here, VASO is a small-cap operating turnaround that has to keep proving itself quarter by quarter. The deferred revenue base says the demand is there. SG&A discipline and the Q2 cash flow print will say whether management can convert it.

The next decision point is Q2 earnings - specifically whether operating cash flow normalizes and whether SG&A growth slows. If both happen against another quarter of deferred revenue growth, the thesis transitions from “mispricing closing” to “quality compounder at fair value,” and the position works for a longer hold.

If Q2 looks like Q1 on cash and SG&A, the asymmetry has tightened enough that taking the gain is the right move for me.

Either way, the original thesis worked. Now we find out what kind of company VASO actually is.

One Discounted Annual Subscription

This post is free. The original VASO thesis wasn’t - paid subscribers got it on November 18 at $0.14, before the 64% move you just read about.

The next idea is already in the pipeline. If you want it when it comes out, I’m putting out one discounted annual subscription code here:

Get 25% Off!

It’s 25% off, and it goes to whoever claims it first through the link above.

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

Six weeks ago I published a deep dive on a name almost nobody was talking about.

Today the stock is up roughly 66%, the company has just reported its first GAAP-profitable quarter (a milestone that was not on management’s calendar for 2026), and every leg of the original thesis is starting to show up in the numbers.

What I find more exciting than the move itself is that this is not the only name doing this right now.

Across the archive, several of the names we have covered over the past year are inflecting at the same time. Earnings prints are confirming theses. Operating leverage is starting to land. Optionality stacks are widening.

We may be on the verge of our first multi-bagger, and possibly more than one.

Upgrade Subscription

For paid subscribers below:

• The full Q1 update on this idea.

• The new numbers worth watching.

• What changed in the option stack.

• How the valuation looks after the move.

• And my updated view on the stock from here.

Read more

To read our full disclaimer, click here.

A profitable medical-consumables microcap spent the last two years signing up hospitals faster than its revenue could show it.

• 58% gross margins - 500 to 1,000+ basis points above its much larger peers.

• Completely debt-free, with net cash worth roughly a third of the market cap.

• A $4 million special dividend paid last quarter, and the cash balance still went up.

• 99% retention of its top-50 hospital accounts.

• Two system-wide approvals at major US hospital networks, one with more than 300 sites of care.

• Roughly 50% insider ownership, with the board alone holding about half the shares.

Yet it trades right around 1x revenue.

Upgrade Subscription

The reason comes down to a single quarter. The company just reported revenue down 15% year over year - a genuinely soft print - and the market took that as the whole story.

I think that’s the mistake. The quarter wasn’t a broken business, it was order timing. Management disclosed that sales and firm orders booked in just the first six weeks of the current quarter had already passed the entire prior quarter’s revenue.

So the downside here is a debt-free, cash-rich, high-margin business. The upside is what happens when one timing quarter stops being the headline.

That’s the asymmetry I look for.

The company is...

Read more

To read our full disclaimer, click here.

Most investors avoid microcap healthcare companies like the plague.

Too risky.

Too volatile.

Too many failed trials.

They'd rather chase the latest AI darling or buy another index fund.

But, if I could invest in only one strategy for the rest of my life, it would be finding asymmetric bets in healthcare microcaps.

Not because it's predictable.

But because it's where the biggest mispricings hide in plain sight.

Healthcare microcaps offer the purest form of asymmetric risk-reward in public markets.

When a $50 million biotech discovers a breakthrough treatment, it doesn't become a $60 million company.

It becomes a $5 billion company.

That's the kind of optionality most investors never see.

Subscribe now

The Edge Hidden in Plain Sight

Healthcare is different from every other sector.

In software, you're betting on adoption curves and network effects.

In healthcare, you're betting on scientific breakthroughs that can't be disrupted.

When a small company solves a real medical problem with a defensible solution, the market doesn't just reward it – it transforms it.

Think about Moderna pre-COVID. A $6 billion company that most investors ignored.

The mRNA platform wasn't sexy. The financials weren't pretty. The path to profitability was unclear.

But the optionality was enormous.

One pandemic later, Moderna hit a peak market cap of $185 billion.

That's not a fluke.

That's what happens when optionality meets opportunity in healthcare.

Why Most Investors Get This Wrong

The traditional value investing playbook breaks down in healthcare microcaps.

You can't screen for low P/E ratios – most don't have earnings.

You can't demand fortress balance sheets – R&D burns cash.

You can't avoid volatility – binary events move stocks 50%+ overnight.

Instead, you need to think like a venture capitalist with a public market toolkit.

Risk management isn't about avoiding volatility.

It's about controlling position sizes and maximizing optionality.

Small bets.

Huge potential outcomes.

Mathematical expectancy in your favor.

My Framework: Optionality Over Everything

Here's how I think about healthcare microcaps:

💡 Look for Multiple Shots on Goal

• Pipeline diversity across indications

• Platform technologies with broad applications

• Regulatory pathways that create locked-in advantages

💡 Focus on Real Problems, Not Imaginary Markets

• Diseases with genuine unmet medical need

• Clear regulatory pathways to approval

• Willing-to-pay customers (patients, insurers, health systems)

💡 Back Founder-Led Teams with Skin in the Game

• Management owns meaningful equity

• Track record of value creation

• Deep domain expertise, not just MBA credentials

💡 Find Narrative Dislocation

• Market story lags scientific reality

• Temporary setbacks create permanent discounts

• Catalyst-rich environments with binary outcomes

Position Sizing: The Key to Asymmetric Investing

Here's how I structure positions:

• Initial positions: 1-2% – Small enough that total loss doesn't matter

• Conviction adds: Up to 5% – As catalysts approach and data validates thesis

• Home runs: Let them run – When optionality hits, don't cap the upside

The math is simple: Lose 1x on the failures, make 10-100x on the winners.

I only need to be right 10-20% of the time to generate life-changing returns.

What This Newsletter Will Cover

Healthcare microcaps aren't for everyone.

They're volatile.

They're complex.

They require patience and conviction.

For every 1,000 microcap healthcare companies, maybe 1 or 2 have legitimate asymmetric potential with the right combination of science, management, and market opportunity.

That's why this newsletter exists.

I release investment theses of 2-4 healthcare microcaps each month that meet my criteria:

✅ Asymmetric risk-reward profiles
✅ Multiple shots on goal
✅ Experienced, aligned management
✅ Real problems worth solving
✅ Mispriced optionality

There are simply not enough of these opportunities out there, so we'll only focus on the absolute best candidates we can find.

You can upgrade here if you want to become a paid member:

Subscribe now

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

Thanks to all of the paid subscribers who’ve joined over the past few months and made this one of the fastest-growing healthcare-focused investment newsletters on the platform.

Subscribe now

We’ve now covered 15 different healthcare ideas - wound care microcaps, telehealth infrastructure platforms, specialty pharma pulling share from 20-year monopolies, surgical pure-plays, rare disease rollups, cash-backed biotechs, diagnostics turnarounds, government biodefense, Canadian chronic pain clinics, pediatric oncology, in-home ventilators, and antimicrobial testing labs.

Here's how I think about every name on the list:

• Invest before the crowd understands.

• Bet asymmetrically.

• Multiple shots on goal. The thesis shouldn’t depend on one thing breaking right.

• Hold through the messy middle. The best ideas rarely move in a straight line.

• Optionality over predictability.

Below is a short thesis summary for every single idea covered on The Clinical Edge to date.

A few of these are free for everyone to read - so if you’re not yet subscribed, this is your chance to see the quality of our work firsthand.

For those considering a subscription: you’re not just getting these 15 ideas. You’re getting continued coverage of every one of them, 2-4 new ideas every month, access to the full Clinical Edge Index tracking every pick in real time, and a new research portal coming soon making it even easier to follow and view all our research.

Annual subscriptions are $400/year - that’s $33 a month versus $50 on the monthly plan. Prices are going up later this year, so lock in today’s rate now:

Upgrade Subscription

I hope you enjoy today’s post…

Stock 1

A wound care microcap built around a proprietary low-frequency ultrasound platform used to treat chronic wounds. The model is razor-and-blade: place systems into wound care clinics, then collect high-margin consumables revenue every time a patient is treated. FY25 revenue grew 35% to $44.1M, adjusted EBITDA nearly doubled to $13.6M, gross margins hit 77.1%, and 624 systems were placed versus 374 in 2024. The miss came on the top line. Management had originally guided $48-50M before CMS cut skin substitute reimbursement by 90-95% mid-year, taking out a chunk of the customer base that ran skin subs alongside the company’s product. The product’s own reimbursement code was unaffected and even got a small bump for 2026. Debt was refinanced with a tier-one bank, Q4 interest expense fell from $2.7M to $603K, and a reseller channel that wasn’t in the original thesis grew to 32% of Q4 revenue. The 2026 setup turns on three questions: did consumables churn bottom in Q4, do reseller placements convert into recurring orders, and does the implied back-half acceleration in management’s +16-25% full-year guide actually arrive.

Stock 2

A Canadian-listed digital health platform that quietly built the regulatory and operational infrastructure every direct-to-consumer telehealth business in America needs. Telemedicine technology, 50-state physician oversight, 503A and 503B pharmacy networks, and a modular B2B2C product that lets entrepreneurs launch a nationwide telehealth brand in days rather than months. The original thesis was simple: this was Shopify-for-healthcare with regulatory moats that actually mattered, riding the GLP-1 wave alongside TRT, peptides, hair loss, and sexual health. Q3 revenue grew 132% YoY and the business posted its fourth consecutive profitable quarter, but the stock then sold off in a single session after management fumbled basic KPI questions on the earnings call. The underlying numbers held: roughly 887K cumulative orders since platform launch, $18.6M cash, no debt. Since then: a December at-home STI testing distribution agreement with 50,000 pre-orders, FY26 baseline revenue guidance of approximately $150M at 15-17% adjusted EBITDA margin, a $15M bought deal led by Canaccord, and a March strategic investment in a buccal semaglutide platform that, if validated, would enable needle-free peptide delivery through the inner cheek. The infrastructure moat is real. The communication question is what management has to keep proving.

Subscribe now

Stock 3

A specialty dermatology pharma launching a new oral rosacea treatment into a $1.2 billion market that one drug had owned for 20 years. The Phase 3 head-to-head data showed 61% greater inflammatory lesion reduction than the incumbent and 28% greater than placebo, with patent protection until 2039. The CEO owns more than 10% of the company. The strategic partner owns 42%. The entire 50-rep commercial team came from a predecessor specialty pharma that sold to Bausch for $2.5B in 2012. They already call on these dermatologists every day, so adding the new product required zero additional infrastructure investment. FY25 revenue came in at $61.9M (+10%), with the new product contributing $14.7M in its partial year, roughly 53,000 prescriptions filled, gross margins improving to 66.2%, and the company flipping to positive adjusted EBITDA. Payer access expanded from 54M commercial lives in May 2025 to 100M+ by year-end, and an April 2026 contract with the third major group purchasing organization pushed access to 85% of all US commercial lives. The lever now shifts from access to formulary adoption, and as that happens, reliance on the co-pay bridging program declines and brand profitability improves.

Stock 4

A precision medical device manufacturer that designs and machines the powered surgical handpieces used in orthopedic and spine procedures. Roughly 75% of revenue comes from a single customer (their largest), which sounds like a screen-killer until you understand it’s an FDA-regulated, micron-tolerance product line with switching costs measured in years and a relationship that just got extended through December 2028, with minimum purchase volumes locked in for 2026 and 2027. FY25 net income quadrupled to $9.0M on $66.6M of sales (+24%), and the entry point was paying for the existing business at a discount while getting a free option on the next-generation handpiece ramp and a position in a publicly-traded robotics company that was subsequently acquired by Zimmer Biomet. That acquisition generated $8.9M in cash plus a 15-year supply agreement opportunity if the robotic platform is commercialized. H1 FY26 revenue grew 17% to $37.2M, EPS of $2.07, gross margin recovered to 31% after a Q4 tariff-driven compression, and management completed the acquisition of a long-time machining supplier with ITAR registrations to secure capacity ahead of the next leg of growth.

Stock 5

A specialty pharma quietly building one of the largest rare disease portfolios in the United States. The playbook: acquire orphan drugs in markets too small for Big Pharma to bother with, then actually invest in patient support, payer access, and physician education. At the time of original coverage, the company had 8 FDA-approved products generating cash, 5 development candidates, 19 consecutive quarters of sequential revenue growth, and 18x forward earnings on a story that was inflecting toward 75% gross margins. Five months later, virtually every catalyst hit. The lead pipeline candidate (oral desmopressin for central diabetes insipidus) was approved with no age restriction, opening 9,000-10,000 adult patients on top of the original 3,000-4,000 pediatric estimate. FY25 revenue more than doubled to $80M. Q4 adjusted gross margin recovered to 73%, EBITDA margin hit 29%, and the company turned GAAP profitable. Management acquired an additional commercial product (the only FDA-approved treatment for infantile hemangiomas) for $14M cash, expanding to 10 commercial products and adding pediatric dermatology as a third commercial call point. New long-term targets: a $200M revenue run rate by end of 2027, 50% adjusted EBITDA margins by 2028, and $500M in revenue by 2030. Built primarily off existing assets without assuming any new business development.

Stock 6

A profitable, three-segment healthcare company that, at the time of coverage, was trading below its own cash balance. The market saw a sleepy OTCQX ticker. The pieces of the story: 87% recurring revenue in the IT services segment (network and managed services), an exclusive sales agency for one of the largest medical device companies in the world covering its diagnostic cardiology and cardiopulmonary equipment in specific US territories, and a proprietary cardiovascular device line. The thesis hinged on a new VP of Operations hired directly from the partner organization to fix a booking-to-revenue conversion bottleneck. Bookings were running ahead of recognized revenue and the operations team couldn’t process them fast enough. Two months after coverage, the partnership agreement was extended through 2030, eliminating the single biggest existential risk. The underperforming healthcare IT reseller was divested. FY25 revenue hit a record $89.1M with $9.3M of operating cash flow and cash up to $35.1M. A five-year-locked partner relationship, a clean balance sheet, and an operations leader from the partner side now positioned to actually convert the bookings backlog into recognized revenue.

Subscribe now

Stock 7

A molecular diagnostics microcap that became a thyroid-only business in 2025 after losing Medicare reimbursement for its pancreatic cancer test. The market saw a 29% headline revenue decline and moved on. What it missed: the thyroid business that remained, a dual-test platform combining a next-generation sequencing oncogene panel with a microRNA expression classifier used by oncologists and endocrinologists to determine whether thyroid nodules require surgery, was growing 22% on a pro forma basis with 62% gross margins and roughly $4M in run-rate net income. At the time of original coverage, the entire business traded at 9x earnings and 1x revenue. Two healthcare-focused private equity firms controlled 84% of equity. Six weeks later, every piece of optionality was in motion: 2025 thyroid revenue grew 21% to roughly $35M, 2026 guidance set at $40M (+16%), all preferred stock was converted to common (the PE sponsors voluntarily gave up their liquidation preference), 100% of debt was paid off in December, and management formally announced intent to pursue a Nasdaq uplisting in 2026. FY25 thyroid volumes grew 13%, average revenue per test rose 5%, DSO dropped 19%, and the clean balance sheet now supports both organic acceleration and the relisting path.

Stock 8

A surgical products company that just made a decisive strategic pivot. Management shut down an unprofitable wound care services segment to focus entirely on what was working: an activated collagen product for tissue closure, a no-rinse antimicrobial surgical irrigation solution, and a small but growing bone fusion line. The company crossed $100M in trailing revenue with 93% gross margins, +22% YoY growth, and EBITDA expanding faster than revenue thanks to a 400+ contracted distributor network leveraging a small internal sales team. The pipeline added a free option: a synthetic injectable bone adhesive with FDA Breakthrough Device Designation, 40x stronger than calcium phosphate per preclinical data, targeting 100,000+ peri-articular fractures annually with a Q1 2027 launch planned. FY25 confirmed the operating leverage thesis. Revenue $103.1M (+19%), gross margin 93%, adjusted EBITDA up 86% to $17M, the discontinued segment is fully wound down, and an Innovative Technology contract with a major group purchasing organization opens 1,800 new facilities in 2026. Q4 was noisy on the surface (5% reported growth distorted by a hurricane comp; 13% adjusted) and the debt balance went up rather than down. The base business is fine. The refinancing window opens in April 2026, the bone adhesive program remains on track, and whether the next 12 months reaccelerate growth back into the high teens is the central question.

Stock 9

A nano-cap cancer diagnostics company that just hit its operational inflection point. Q3 2025 was the first quarter in its history with positive adjusted EBITDA ($469K), positive operating cash flow ($285K), and revenue growth of 30% YoY. Two revenue streams, both inherently recurring: a CLIA-certified molecular and cytogenetic lab serving community oncologists who lack in-house testing capability (roughly 90% of revenue, sticky monthly oncology test volume), and a Products division selling proprietary reagent kits and assay panels (10% of revenue, growing 15-20% quarterly at roughly 60% contribution margins). Gross margins climbed from 43% to 46% during 2025, with management targeting above 50% by mid-2026. The Change Healthcare cyberattack disruption that had hammered collections through 2024 was fully resolved, billing normalized, and the company moved from cash-strapped to self-funding. At 1.6x EV/Sales versus diagnostic peers at 3-5x, this was overlooked optionality on a recurring revenue platform with structural operating leverage. Preliminary FY25 results landed at $24M revenue (+30% YoY), Q4 adjusted EBITDA of $0.95M, and full-year operating cash flow of $688K. At the current valuation gap to peers, the re-rate likely has further to run if execution continues.

Stock 10

A specialty life sciences company that two years ago was left for dead. Manufacturing failures, regulatory scrutiny, and a balance sheet drowning in acquisition debt. The company quietly transformed itself into a cash machine. Two engines: Medical Countermeasures (anthrax, smallpox, botulism, and Ebola products sold to BARDA, the Department of Defense, and the Strategic National Stockpile) and a leading naloxone franchise. At the time of original coverage, the YTD swing was striking: net income flipped from negative $159M to positive $107M, SG&A was cut roughly in half, net leverage fell from 3.3x to 2x, and cash nearly tripled. International MCM jumped from the mid-teens to 34% of segment revenue. FY25 closed with $205M adjusted EBITDA (above guide), $110M of debt paid down, $171M operating cash flow (+53%), and $87M adjusted net income. Q4 was ugly. Revenue declined 24% on the government shutdown hitting naloxone sales to public-interest customers and segment gross margin collapsed to 6%. The 2026 guide implies a roughly 30% EBITDA step-down, partly because a $60M one-time international order doesn’t repeat and partly because management is reinvesting in growth. Real catalysts since the update: a $54M smallpox immunoglobulin contract from ASPR, a $140M CAD multi-product Canadian biodefense agreement, a refinanced term loan with OrbiMed (interest down 200bps, maturity extended to April 2031), a $34.5M Japanese encephalitis vaccine manufacturing partnership with US distribution rights, and a multi-year manufacturing agreement worth roughly $50M to support a Type 1 diabetes program. The turnaround happened. Whether the pivot to growth materializes is the harder bet.

Stock 11

A pre-revenue biotech whose entire existence rests on solving the most important unsolved problem in cancer biology: drugging mutant p53. p53 is the “guardian of the genome.” When it works, it detects DNA damage and triggers cancer cell death. When it breaks, cancer runs unchecked. It’s mutated in more than half of all human cancers, and for 40 years the field has considered it undruggable. The lead candidate is a first-in-class small molecule designed to bind a specific mutation-induced pocket in the p53 Y220C variant and structurally restore the protein’s normal function. Phase 2 PYNNACLE data: 34% overall response rate across 103 evaluable patients (median three prior lines of therapy), 46% in ovarian cancer, 79% disease control rate, with a clean safety profile. FDA Fast Track since 2020, Orphan Drug Designation March 2026, NDA filing target Q1 2027. Patents through the 2040s. Zero late-stage competition - the closest prior attempt failed Phase 3 in 2022. At the time of original coverage, the company had $112.9M in cash against a market cap roughly $30M lower. The entire pipeline traded at negative enterprise value. Single-asset binary biotech, cash through Q2 2027, probability-weighted expected value roughly 10-12x the current market cap on illustrative scenarios.

Subscribe now

Stock 12

Canada’s largest dedicated chronic pain clinic network, operating regulated medical facilities across Ontario and Alberta where pain specialists deliver injections, nerve blocks, radiofrequency ablation, ketamine infusions, and newer procedures including an injectable osteoarthritis treatment for chronic knee pain. 97-99% of revenue is government-funded through provincial health insurance programs. Recurring, payer-stable, with structural demand that isn’t going away (1,200+ patients on a single clinic’s waitlist; 18-month wait times for pain specialists in some markets). Q3 2025 revenue grew 26% to $22.1M with adjusted EBITDA nearly doubling to $1.5M as capacity utilization climbed from 73% to 84%. 27 consecutive quarters of positive EBITDA. Net debt under $2M, no warrants, no convertibles, no messy capital structure. The CEO has been buying personally, the company is buying back stock through its NCIB, all outstanding warrants have been retired, and management has 10-12 acquisition targets under active evaluation with bank financing already secured. The stock trades at roughly 5x trailing EV/EBITDA versus comparable Canadian healthcare clinic operators at 7-11x. The simplest re-rate to the low end of the peer range implies meaningful upside. To the middle of the range, more than a double. And that’s before the acquisition pipeline does any work.

Stock 13

A specialty pharma with a single product. But it’s the only FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss in pediatric cancer patients. A real clinical breakthrough in a category where oncologists have spent decades watching children lose their hearing as the price of curative chemotherapy. FY25 net product sales grew 51% to $44.6M, with Q4 revenue +75% YoY and five consecutive quarters of growth. The balance sheet was transformed during 2025. More than $42M in equity raised, all debt fully redeemed, year-end cash of $36.8M, zero debt. A patent litigation settlement extends generic-free runway to at least September 2033. The real story from here isn’t the existing pediatric business. It’s the adolescent and young adult market, which is roughly 10x the size of the pediatric indication where cisplatin use is far more common. A large community oncology practice has already added the product to formulary, the field force has been expanded for the first time in years, top-3 payer reimbursement is running at 95-100%, and a European partner is planning 8-10 launches in 2026 (UK and Germany already live). Positive Phase 2/3 results in Japan support a registration strategy in another major market. Operating expense steps up sharply in 2026 ($35M to $50M) as the company invests in the AYA expansion. Roughly 19% of the market cap is backed by net cash, before any credit for the 10x market expansion in front of it.

Stock 14

A multi-engine in-home medical equipment platform. The company keeps very sick patients out of the hospital by setting up clinical equipment in their living rooms and getting paid a monthly Medicare rental fee for as long as therapy continues. Four pieces: in-home ventilators for end-stage COPD patients (51% of revenue, multi-year retention, proprietary adherence software), PAP devices and resupply for sleep apnea (printer-and-ink economics, with GLP-1 adoption creating a real diagnostic tailwind as more patients sit in front of doctors), maternal health (a 2025 acquisition added breast pumps and related products plugged into a nationwide insurance footprint that the acquired business could never have reached on its own), and a smaller oxygen, airway clearance, and hospital staffing business. FY25 revenue grew 21% to $270.3M with record adjusted EBITDA of $61.4M (22.7% margin), and company-defined free cash flow more than doubled to $28.1M. Balance sheet is essentially net cash. The biggest overhang of the last two years, a National Coverage Determination update for in-home non-invasive ventilation, has shifted from active threat to improving setup, with 100% appeal success at the administrative law judge level and January 2026 reportedly one of the strongest setup months in company history. 2026 guidance: $310-320M revenue (+17% ex-M&A), $65-69M adjusted EBITDA. Active buyback just renewed for 2026.

Stock 15

A Canadian regulated antimicrobial and biofilm contract testing lab serving medical device manufacturers, pharmaceutical companies, and biotech sponsors who need to satisfy FDA, Health Canada, and European regulators that their devices don’t grow dangerous biofilms. The work is required (not discretionary), methodology-heavy, and accreditation-dependent. Once a client validates a test method with the lab and submits it to a regulator as part of a device file, switching means redoing the validation work and re-justifying it. FY25 revenue more than doubled to C$4.53M (the legacy lab grew 59% organically; the rest came from a 2024 acquisition that added analytical chemistry and GMP microbial testing into the platform). Gross margin 52.9%, adjusted EBITDAS up 238% on 107% revenue growth, profitable in 3 of 4 quarters with Q4 closing the year at a 22% EBITDAS margin. Net cash on the balance sheet covers roughly 12% of equity value. On April 14, 2026, the company began trading on the OTCQB. US capital can now access the stock without friction for the first time. Free optionality on a proprietary silver-based antimicrobial IP platform, a research-grade product line that is the only commercially validated tool for what it does, an enhanced 35% refundable Canadian R&D tax credit just substantively enacted, and an active M&A pipeline ranging from tuck-in to potentially transformational. Sweet spot of investable and under-followed.

Subscribe now

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

Note: The scenarios, probabilities, and potential return estimates discussed in this post reflect my personal assumptions and framework for thinking about risk-reward. They are not guarantees, predictions, or investment advice. Always do your own research.

Every medical device that goes inside a human body has to pass a specific set of tests.

Catheters. Implants. Injectables. Surgical mesh. Wound care products.

The question regulators want answered is simple: can bacteria colonize this device and form biofilms?

The FDA requires testing. Health Canada requires testing. European regulators require testing.

It’s a regulatory checklist item, not a “nice to have.”

And the testing isn’t simple.

It takes custom methodologies, specialized equipment, accredited quality systems, and years of relationship-building between client and vendor. Once a client validates a method with a particular lab, switching means redoing the work and re-justifying it to the regulator.

In North America, only a handful of labs are qualified to do this work at the highest level.

One of them is a microcap that’s just doubled its revenue, was profitable in three of four quarters in 2025, sits on a net cash balance sheet, and started trading in the United States for the first time a few weeks ago.

Upgrade Subscription

Here’s what makes this interesting:

• Required spend, not discretionary spend. Customers don’t have a choice. Antimicrobial and biofilm testing is a regulatory line item on the path to FDA clearance.

• Real operating leverage. Adjusted EBITDAS grew 238% on 107% revenue growth in FY2025. The ratio matters more than the absolute numbers at this scale.

• Net cash balance sheet. Net cash covers roughly 12% of the equity value, with no externally imposed financial covenants and a current ratio of 5.79.

• Profitable in three of four quarters in 2025. Q4 closed the year with an Adjusted EBITDAS margin of 22%.

• Active M&A pipeline. Management has flagged tuck-in, bolt-on, and potentially transformational acquisitions actively under evaluation for 2026.

• Free optionality. A proprietary antimicrobial IP platform, a research-grade product line, and a recently enhanced refundable R&D tax credit. None of that is reflected in the current financials.

• Listing catalyst. US capital can now access the stock without friction for the first time.

My rough scenario assumptions (not predictions, just how I’m framing the risk-reward):

• Stagnation / deceleration (~30% probability): Organic revenue growth slows to single digits, M&A pipeline stalls, the operating leverage thesis fades. Stock drifts back toward C$0.13-0.15. Downside: ~25-35%.

• Base case (~50% probability): 25-30% revenue growth in 2026, Adjusted EBITDAS margin expands to 13-15%, market re-rates to ~10-12x forward EBITDAS as US investors discover the listing. Upside: ~75-100%.

• Bull case (~20% probability): Tuck-in M&A executes accretively, organic growth holds in the 40%+ range, EBITDAS margin reaches 18-20%, multiple expands toward US-listed CRO peers in the 12-18x range. Upside: ~3-5x.

• Probability-weighted expected return: roughly 80-130% from current levels against limited downside given the cash floor and the operating earnings already on the table.

The company is...

Read more

To read our full disclaimer, click here.

The company I'm sharing today is a rare case that checks the following boxes:

• High-quality, recurring revenue from medical equipment rentals to chronically ill patients

• 21% revenue growth in 2025, with record Adjusted EBITDA and free cash flow that more than doubled

• Near-zero net debt, active board-authorized buyback - just renewed for 2026

• The 2025 buyback was executed at an average price 38% below where the stock trades today

• The biggest regulatory overhang of the last two years just shifted from active threat to improving setup

• Multiple growth engines layered on top of the core: sleep/resupply compounding, maternal health scaling, tuck-in M&A optionality

• ~$357M market cap, limited sell-side coverage (the sweet spot of investable and under-followed)

• Trades at ~5.3x 2026 EBITDA while healthcare services peers fetch 8-10x, with management guiding another year of strong growth

Upgrade Subscription

I like each of these properties a lot, but rarely find them all in one stock.

After watching it trade sideways under a regulatory cloud for two years, the Q4 print and 2026 guidance confirmed the story is finally moving in the other direction - and the market is only starting to reprice.

Read more